https://it.marketscreener.com/quotazioni/azione/AVALO-THERAPEUTICS-INC-23733730/attualita/Avalo-annuncia-i-dati-principali-dello-studio-di-Fase-2-Peak-per-Avtx-002-Quisovalimab-nei-pazient-44188357/?utm_source=telegram&utm_medium=social&utm_campaign=share